Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy

International Immunopharmacology

Volumn 10, Issue 2, 2010, Pages 207-212

  Koch, Matthias ^a   Savvatis, Konstantinos ^a   Scheeler, Michael ^a   Dhayat, Sameer ^a   Bonaventura, Klaus ^a   Pohl, Thomas ^b   Riad, Alexander ^a   Bulfone Paus, Silvia ^b   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Immunology and Cell Biology Borstel ^*  (Germany)

Author keywords

Fusion protein; Hemodynamics; Interleukin 2; Ischemia; Remodeling

Indexed keywords

COLLAGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G2B INTERLEUKIN 2 FUSION PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ANIMALS; FIBROSIS; HEMODYNAMICS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INTERLEUKIN-1; INTERLEUKIN-2; MALE; MYOCARDIAL ISCHEMIA; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION;

EID: 74749086220     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.11.001     Document Type: Article

References (36)

1. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 20 Suppl 4 (Nov 14 2000) IV14-IV23
2. Sharma R., Coats A.J., and Anker S.D. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol 72 2 (Jan 15 2000) 175-186
3. Paulus W.J. Cytokines and heart failure. Heart Fail Monit 1 2 (2000) 50-56
4. Balakumar P., and Singh M. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 99 6 (Dec 2006) 391-397
5. Birks E.J., and Yacoub M.H. The role of nitric oxide and cytokines in heart failure. Coron Artery Dis 8 6 (Jun 1997) 389-402
6. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., and Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 9 3 (2007) 236-241
7. Fukunaga T., Soejima H., Irie A., Sugamura K., Oe Y., Tanaka T., et al. Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 100 3 (Aug 1 2007) 483-488
8. Kaur K., Sharma A.K., and Singal P.K. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 291 1 (Jul 2006) H106-H113
9. Stumpf C., Seybold K., Petzi S., Wasmeier G., Raaz D., Yilmaz A., et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail 10 8 (Aug 2008) 733-739
10. Herskowitz A., Choi S., Ansari A.A., and Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 146 2 (Feb 1995) 419-428
11. Limas C.J., Goldenberg I.F., and Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation 91 3 (Feb 1 1995) 631-634
12. Marriott J.B., Goldman J.H., Keeling P.J., Baig M.K., Dalgleish A.G., and McKenna W.J. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 75 3 (Mar 1996) 287-290
13. Adamopoulos S., Parissis J.T., and Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 5 (Oct 2001) 517-526
14. Kragel A.H., Travis W.D., Steis R.G., Rosenberg S.A., and Roberts W.C. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66 7 (Oct 1 1990) 1513-1516
15. Fragasso G., Tresoldi M., Benti R., Vidal M., Marcatti M., Borri A., et al. Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer. Br Heart J 71 2 (Feb 1994) 166-169
16. Malek T.R. The biology of interleukin-2. Annu Rev Immunol 26 (2008) 453-479
17. Malek T.R., and Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4 9 (Sep 2004) 665-674
18. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30 5 (May 2009) 636-645
19. Cleutjens J.P., Blankesteijn W.M., Daemen M.J., and Smits J.F. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 44 2 (Nov 1999) 232-241
20. Tschope C., Spillmann F., Altmann C., Koch M., Westermann D., Dhayat N., et al. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res 61 3 (Feb 15 2004) 559-569
21. Tschope C., Heringer-Walther S., Koch M., Spillmann F., Wendorf M., Hauke D., et al. Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J Hypertens 18 2 (Feb 2000) 223-228
22. Kunzendorf U., Pohl T., Bulfone-Paus S., Krause H., Notter M., Onu A., et al. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. J Clin Invest 97 5 (Mar 1 1996) 1204-1210
23. Kunzendorf U., Pohl T., Bulfone-Paus S., Krause H., Ziegler E., Onu A., et al. Immunomodulation in experimental and clinical nephrology using chimeric proteins. Kidney Blood Press Res 19 3-4 (1996) 201-204
24. Tschope C., Walther T., Escher F., Spillmann F., Du J., Altmann C., et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19 14 (Dec 2005) 2057-2059
25. Noutsias M., Pauschinger M., Ostermann K., Escher F., Blohm J.H., Schultheiss H., et al. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 8 5 (May 2002) MT59-MT71
26. Tschope C., Walther T., Koniger J., Spillmann F., Westermann D., Escher F., et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18 7 (May 2004) 828-835
27. Opie L.H., Commerford P.J., Gersh B.J., and Pfeffer M.A. Controversies in ventricular remodelling. Lancet 367 9507 (Jan 28 2006) 356-367
28. Frangogiannis N.G. The immune system and cardiac repair. Pharmacol Res 58 2 (Aug 2008) 88-111
29. Ruckert R., Brandt K., Hofmann U., Bulfone-Paus S., and Paus R. IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. J Invest Dermatol 119 2 (Aug 2002) 370-376
30. Stallmach A., Wittig B., Giese T., Pfister K., Hoffmann J.C., Bulfone-Paus S., et al. Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin 2-IgG2b fusion protein in mice. Gastroenterology 117 4 (Oct 1999) 866-876
31. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., and Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311 5769 (Mar 31 2006) 1924-1927
32. Webster K.E., Walters S., Kohler R.E., Mrkvan T., Boyman O., Surh C.D., et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 206 4 (Apr 13 2009) 751-760
33. Riley J.L., June C.H., and Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30 5 (May 2009) 656-665
34. Blattman J.N., Grayson J.M., Wherry E.J., Kaech S.M., Smith K.A., and Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 9 5 (May 2003) 540-547
35. Westermann D., Van Linthout S., Dhayat S., Dhayat N., Escher F., Bucker-Gartner C., et al. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56 7 (Jul 2007) 1834-1841
36. Westermann D., Van Linthout S., Dhayat S., Dhayat N., Schmidt A., Noutsias M., et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 102 6 (Nov 2007) 500-507